233 related articles for article (PubMed ID: 28302215)
1. [Altered Treg and IL-1A Expression in the Immune Microenvironment
of Lung Squamous-cell Cancer after EGFR Blockade].
He H; Qi L; Hou Y
Zhongguo Fei Ai Za Zhi; 2017 Mar; 20(3):143-148. PubMed ID: 28302215
[TBL] [Abstract][Full Text] [Related]
2. Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas.
Mascia F; Schloemann DT; Cataisson C; McKinnon KM; Krymskaya L; Wolcott KM; Yuspa SH
Int J Cancer; 2016 Dec; 139(11):2593-7. PubMed ID: 27509256
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
4. Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.
Wright LN; Ryscavage A; Merlino G; Yuspa SH
Clin Cancer Res; 2012 Jan; 18(1):170-83. PubMed ID: 22068661
[TBL] [Abstract][Full Text] [Related]
5. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
6. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
7. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma.
Zhang S; Fujita H; Mitsui H; Yanofsky VR; Fuentes-Duculan J; Pettersen JS; Suárez-Fariñas M; Gonzalez J; Wang CQ; Krueger JG; Felsen D; Carucci JA
PLoS One; 2013; 8(5):e62154. PubMed ID: 23667456
[TBL] [Abstract][Full Text] [Related]
8. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA; Koyama S; Carretero J; Altabef A; Tchaicha JH; Christensen CL; Mikse OR; Cherniack AD; Beauchamp EM; Pugh TJ; Wilkerson MD; Fecci PE; Butaney M; Reibel JB; Soucheray M; Cohoon TJ; Janne PA; Meyerson M; Hayes DN; Shapiro GI; Shimamura T; Sholl LM; Rodig SJ; Freeman GJ; Hammerman PS; Dranoff G; Wong KK
Cancer Discov; 2013 Dec; 3(12):1355-63. PubMed ID: 24078774
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10. Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
Lorch G; Gilmore JL; Koltz PF; Gonterman RM; Laughner R; Lewis DA; Konger RL; Nadella KS; Toribio RE; Rosol TJ; Foley J
Br J Cancer; 2007 Jul; 97(2):183-93. PubMed ID: 17533397
[TBL] [Abstract][Full Text] [Related]
11. Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis.
Wang S; Zhang Y; Wang Y; Ye P; Li J; Li H; Ding Q; Xia J
J Biol Chem; 2016 Sep; 291(40):21085-21095. PubMed ID: 27432879
[TBL] [Abstract][Full Text] [Related]
12. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma.
Mataki H; Seki N; Chiyomaru T; Enokida H; Goto Y; Kumamoto T; Machida K; Mizuno K; Nakagawa M; Inoue H
Int J Oncol; 2015 Mar; 46(3):1039-50. PubMed ID: 25522678
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
14. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
[No Abstract] [Full Text] [Related]
15. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.
Verone-Boyle AR; Shoemaker S; Attwood K; Morrison CD; Makowski AJ; Battaglia S; Hershberger PA
Oncotarget; 2016 Jan; 7(1):995-1013. PubMed ID: 26654942
[TBL] [Abstract][Full Text] [Related]
16. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
17. MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.
Cataisson C; Michalowski AM; Shibuya K; Ryscavage A; Klosterman M; Wright L; Dubois W; Liu F; Zhuang A; Rodrigues KB; Hoover S; Dwyer J; Simpson MR; Merlino G; Yuspa SH
Sci Signal; 2016 Jun; 9(433):ra62. PubMed ID: 27330189
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis.
Finetti F; Terzuoli E; Bocci E; Coletta I; Polenzani L; Mangano G; Alisi MA; Cazzolla N; Giachetti A; Ziche M; Donnini S
PLoS One; 2012; 7(7):e40576. PubMed ID: 22815767
[TBL] [Abstract][Full Text] [Related]
19. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
